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Abstract The alkaline phospholipase A2 (PLA2) was purified 
from nuclei of rat ascites hepatoma cells (AH7974) by column 
chromatography with a Sephacryl S-300 column and an 
immunoadsorbent using anti-group II PLA2 monoclonal anti- 
body. From these two columns, the alkaline PLA2 was eluted in 
parallel with a 17-kDa protein which is reactive to another anti- 
group II PLA2 polyclonal antibody. Approximately 80% of 
nuclear PLA2 was inhibited by this antibody. The alkaline PLA2 
was found in association with the chromatin fraction among 
subnuclear fractions. By an immunocytochemical staining, the 
nuclei of AH7974 were stained more strongly than other parts of 
cells with anti-group II PLA2 antiserum. 
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1. Introduction 
shown to localize to the Golgi area by immunocytochemical 
study [15]. Thus, the membrane-binding mechanism and the 
subcellular localization of secretory PLA2 remain to be inves- 
tigated. 
We have reported the growth-associated changes of fatty 
acid composition of nuclear phospholipids: the decrease in 
arachidonic and docosahexanoic a ids and the increase in 
oleic acid at S phase of liver regeneration [16]. We also re- 
ported the presence of neutral and alkaline PLA2 in the nuclei 
of rat ascites hepatoma cells (AH7974) [9]. These results raise 
the possibility that an acive acylation-deacylation cycle in nu- 
clei alters the fatty acid moieties of nuclear phospholipids, and 
that it leads to the production of various bioactive substances 
from the released fatty acids and lysophospholipids, respond- 
ing to the diverse growth signals. In the present study, we 
found that the alkaline PLA2 in nuclei of rat ascites hepatoma 
AH7974 cells, was closely related to group II PLA2 and asso- 
ciated with chromatin-rich fraction. 
Phospholipase A2 (PLA~) catalyzes the hydrolysis of the sn- 
2-ester bond of phospholipids and produces the precursors of 
potent lipid mediators, such as leukotrienes, prostaglandins 
and platelet activating factor. In mammalian cells, PLA2 has 
been found in various ubcellular f actions, plasma membrane 
[1,2], Golgi membrane [3], microsome [4], mitochondria [5], 
lysosome [6], and cytosol [7,8]. To date, little information 
concerning nuclei is available, even inclusive of our previous 
report [9]. PLA2 species of mammalian origin have been clas- 
sified into three groups, group I (pancreatic), group II (non- 
pancreatic) and cytosolic, according to their primary struc- 
tures. The former two are often termed 'secretory PLA2'. In 
the last few years, the secretory PLA2 species, especially group 
II PLA2, have been found in the particulate fractions of many 
cells and tissues in spite of the presence of a typical signal 
sequence as a secretory enzyme in its molecule [5,10-12]. 
Further, the subcellular localization of group II PLA2 seems 
to be various in tissues and cells, i.e. mitochondria n liver [5] 
and secretory granules of latent platelets [13] and of mast cells 
[14], while group II PLA2 in rat mesangial cells has been 
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Abbreviations: PLA2, phospholipase A2; [t4C]arachidonyl PE, 1-acyl- 
2-[1-14C]arachidonyl phosphatidylethanolamine; PE, phosphatidyl- 
ethanolamine; PS, phosphatidylserine; PC, phosphatidylcholine; PI, 
phosphatidylinositol; PMSF, phenylmethylsulfonyl fluoride; SDS- 
PAGE, sodium dodecyl sulfate-polyacrylamide gel lectrophoresis; 2- 
ME, 2-mercaptoethanol 
2. Materials and methods 
2.1. Materials 
1-Stearoyl-2-[1-a4 C]arachidonyl-sn-glycero-3-phosphocholine, l- 
acyl-2-[1-14C]arachidonyl phosphatidylethanolamine ([14C]-arachido- 
nyl PE), 1,2-dioleoyl-sn-glycero-phospho-[2-14C]ethanolamine, 1,2-di- 
oleoyl-sn-glycero-phospho-[3-14 C]serine, 1 -palmitoyl-2-[1-14 C]linoleoyl 
phosphatidylethanolamine, and 1 -stearoyl-[1-14C]arachidonyl-sn- 
glycero-3-phosphoinositol were purchased from Amersham Int. plc, 
UK (specific radioactivity of all lipids, 1.85 2.2 GBq/mmol). Anti- 
group II PLA2 serum was raised in rabbits immunized with purified 
group I1 PLA2 from rat platelets. The polyclonal (R377) and mono- 
clonal (MD7.1) antibodies specific for rat group II PLA2 were pre- 
pared as described previously [17,18]. The polyclonal ntibody specific 
for rat pancreatic group I PLA2 was generously gifted by Dr. M. 
Okamoto of Osaka University, Japan. The antibody MD7.l-conju- 
gated Sepharose CL-413 was prepared as described previously [17]. 
Rat group II PLA2 was purified from rat platelets according to the 
method of Mizushima et al. [19]. 
2.2. Preparation of nuclei 
Nuclei were prepared from rat ascites hepatoma cells (AH7974) as 
described previously [9]. The purity of nuclei was estimated to be 
more than 90% based on the activities of 5'-nucleotidase as a plasma 
membrane marker, glucose-6-phosphatase as a microsomal marker 
and cytochrome oxidase as a mitochondrial marker, and also on elec- 
tron microscopic observation [9]. 
2.3. Preparation of subnuclear fractions 
Nuclei were fractionated according to the method of Payrastre et al. 
[20] with some modifications. In brief, the highly purified nuclei (1.5-2 
ml of packed volume, approximately 100-150 mg protein) were incu- 
bated for 7 min in 10 ml of ice-cold solution containing 1% Triton X- 
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100, 100 mM NaC1, 300 mM sucrose, 3 mM MgCl2, 0.5 mM CaCI2, 
0.1 mM phenylmethylsulfonyl fluoride (PMSF) and centrifuged at 
650×g for 5 min. The supernatant was used as nuclear membrane 
fraction. The pellet (membrane-depleted nuclei) was resuspended and 
incubated for overnight at 4°C in 10 ml of a solution containing 50 
mM NaCI, 300 mM sucrose, 10 mM MgCI2, 0.1 mM PMSF, 400 
units of pancreatic DNase I (Takara-Shuzo Co., Japan) and 500 lag 
of pancreatic RNase (Boehringer-Mannheim Biochemicals, Germany). 
Then, 2 M (NH4)2SO4 was added dropwise to the incubation mixture 
to a final concentration of 0.25 M. Nuclear matrices were pelleted at 
10 000 × g for 10 rain and the resulting supernatant was used as chro- 
matin fraction. 
2.4. Purification of PLA2 
All procedures were carried out at 0~°C. Ten ml of chromatin 
fraction prepared from 2 ml of packed nuclei as described above 
was put into a cellophane dialysis tube and concentrated to 2 ml 
with solid sucrose. Two ml of the solubilized PLA2 solution thus 
obtained was applied on a column of Sephacryl S-300 (1.2×85 cm) 
equilibrated with a solution containing 0.25 M (NH4)2SO4, 20 mM 
Tris-HC1 (pH 7.2) and 0.1 mM PMSF. The column was then eluted 
with 200 ml of the same solution used for equilibration. The active 
fractions were pooled and applied onto an immunoaffinity CNBr-Se- 
pharose column (1.5×2 cm) conjugated with a monoclonal antibody 
against rat group II PLA2 (MD7.1) which was equilibrated with a 
solution containing 10 mM Tris-HC1 (pH 7.4), 1 mM EDTA and 1 M 
KC1. The column was washed with 100 ml of the same solution used 
for equilibration and the enzyme was eluted with 20 ml of 20 mM 
glycine/HCI (pH 2.5). The eluate was immediately neutralized with 
1 M Tris base. 
2.5. Determination f PLA2 activity 
The standard assay for PLA2 activity with [14C]arachidonyl PE, 
except where otherwise noted, was carried out at 37°C for 30 rain 
in a reaction mixture (100 lal) containing an appropriate amount of 
enzyme source, 100 mM glycine/NaOH (pH 9.5), 10 mM CaC12, 
0.06% taurodeoxycholic a id, 100 IxM [14C]arachidonyl PE (specific 
radioactivity was adjusted to 3000 cpm/nmol by the addition of un- 
labeled PE). The assays with other phospholipids as substrates were 
carried out under the same conditions as described above. The re- 
leased 14C-labeled fatty acid was determined by a modification of 
Dole's procedure [21]. On the other hand, the released radioactive 
lysophospholipid was separated by thin-layer chromatography and 
its radioactivity determined as described previously [9]. 
For the neutralization of PLA2 activity by the antibodies, the 
pooled active fractions from the Sephacryl S-300 column were prein- 
cubated with various amounts of polyclonal antibodies against rat 
group II PLA~ and rat group I PLA2 in a solution containing 100 
mM glycine/NaOH (pH7.0) and ovalbumin (1 mg/ml) for 30 min on 
ice. The remaining activity was determined under the same conditions 
as described above. 
2,6. SDS-PAGE and immunoblotting analyses 
SDS-PAGE was performed under non-reducing condition on 20% 
polyacrylamide g l according to the method of Laemmli [22]. Individ- 
ual protein bands were visualized using the 2D-SILVER STAIN II 
Kit (Daiichi Pure Chemicals Co., Ltd., Japan). Molecular mass mar- 
kers (Bio-Rad) were lysozyme (14.4 kDa), trypsin inhibitor (21.5 
kDa), carbonic anhydrase (31.0 kDa) and ovalbumin (45.0 kDa). 
For immunoblotting analysis, the electrophoresed proteins were trans- 
ferred to a nylon membrane (Immobilon, Millipore Co., Bedford, 
MA) and probed with the specific polyclonal antibodies against 
PLA2. The immune complex was then visualized with [lzSI]protein 
A and analyzed on a Fujix BAS 2000 image analyzer (Fujix Co. 
Ltd., Tokyo). 
2. 7. Immunocytoehemical an lysis 
Exponentially growing AH7974 cells were fixed with 4% parafor- 
maldehyde and smeared on the slide glass coated with gelatin. The 
cells were immersed in 0.3% Triton X-100 for 30 min, treated with 
10% normal goat serum for 1 h and then with anti-group II PLA2 
serum or non-immune rabbit serum (each dilution, 1:1000 with PBS) 
overnight at room temperature. Subsequent treatments were per- 
formed in the following orders: (1) biotinized anti-rabbit IgG (dilu- 
tion, 1:200 with PBS) for l h, (2) streptavidin-biotin-peroxidase kit 
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(Histofine, Nichirei, Japan) (dilution, 1:100 with PBS) for 1 h, (3) a 
solution containing 0.03% diaminobenzidine and 0.005% H202 for 
5 min. The immunostained cells thus obtained were dehydrated and 
mounted. 
3. Results 
3.1. Subnuclear distribution of alkaline PLA2 
As shown in Fig. 1A, almost all of the alkaline PLA2 ac- 
tivity in intact nuclei was recovered in the chromatin-rich 
fraction, i.e. the 0.25 M (NH4)2SO4 extract from the 1% Tri- 
ton X-100-treated, DNase- and RNase-digested nuclei. 
Further, the immunoreactive 17-kDa protein was detected 
by a polyclonal antibody against rat group II PLA2 in the 
lysates of intact nuclei, membrane-depleted nuclei, and chro- 
matin-rich fractions (Fig. 1B). The total activity in membrane- 
depleted nuclei was always higher than that in intact nuclei, 
suggesting the existence of an inhibitor for PLA2 in nuclear 
extract that is removed by 1% Triton X-100 treatment. In 
connection with this, we found annexin I and II in 1% Triton 
X-100-soluble fraction of nuclei by immunoblotting analysis 
(data not shown). The alkaline PLA2 found in nuclei is not 
due to contamination of endoplasmic reticulum and/or cytosol 
because the denuded nuclei by the treatment with 1% Triton 
X-100 completely retain both the alkaline PLA2 activity and 
immunoreactivity with a polyclonal antibody against group II 
PLA~ (Fig. 1A,B). 
3.2. Purification of alkal&e PLA2 from nuclei 
The efficient solubilization of the nuclear alkaline PLA2 of 
rat ascites hepatoma AH7974 cells was achieved by the ex- 
traction in 0.25 M (NH4)2SO4 of the 1% Triton X-100-treated 
nuclei after digestion with DNase and RNase as shown in Fig. 
1A. Although the nuclear phospholipase C of AH7974 cell 
was well solubilized with 2 M KC1 from intact nuclei [23], 
70% of the nuclear PLA2 remained insoluble under the same 
conditions (data not shown). The solubilized PLA2 prep- 
aration (0.25 M (NH4)2SO4 extract) thus obtained was con- 
centrated, and was subjected to Sephacryl S-300 column gel 
filtration. The activity was eluted as a broad peak, corre- 
sponding to a molecular mass of 40 kDa and lower (Fig. 
2A). On SDS-PAGE/immunoblott ing with a polyclonal anti- 
body against rat group II PLA2, an immunoreactive 17-kDa 
protein appeared in the fractions that contained PLA2 activity 
(data not shown). The broad peak was clearly separated into 
two peaks by rechromatography (Fig. 2B), and only the latter 
peak corresponded to alkaline PLA2 that immunoreacted with 
a polyclonal antibody against group II PLA2 (Fig. 2C). The 
former peak was identified as neutral PLA2 by its pH opti- 
mum [9] and molecular mass which had already been esti- 
mated to be 33 kDa (unpublished ata). These results suggest 
that the broad peak in Fig. 2A may be a mixture of neutral 
and alkaline PLA2. The alkaline PLA2 activity in the pooled 
active fraction (collected from fractions 54-68 in Fig. 2A) was 
inhibited to 20% of original activity by a polyclonal antibody 
against group II PLA2, but not by a polyclonal antibody 
against group I PLA2 under the conditions described in Sec- 
tion 2 (data not shown). The alkaline PLA2 activity in intact 
nuclei was also dose-dependently inhibited by a polyclonal 
antibody against group II PLA2 to 20% at maximum. These 
results indicate that most of the nuclear alkaline PLA2 may 
belong to group II PLA2. The pooled active fraction was 
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subsequently subjected to immunoaffinity column chromatog- 
raphy using an anti-rat group II PLA2 monoclonal antibody- 
conjugated Sepharose. The SDS-PAGE of active fractions, 
eluted from the column with 20 mM glycine/HC1 (pH 2.5), 
revealed protein bands at the position of molecular mass 17 
kDa when visualized by silver staining (Fig. 3A). The protein 
bands were in parallel with the elution pattern of PLA2 activ- 
ity, which was highest in fractions corresponding to lanes 6-8 
of Fig. 3A, assayed as described in Section 2 (data not 
shown). Further, as assessed by SDS-PAGE/immunoblott ing, 
the 17-kDa protein which co-migrated with group II PLA2 
purified from rat platelets was recognized by anti-rat group 
II PLA2 antibody (Fig. 3B). From these results, it is con- 
cluded that the alkaline PLA2 in AH7974 cell nuclei is closely 
related to group II PLA2. The enzyme was finally purified 
735-fold. The apparent Km and Vm~, were determined with 
various concentrations of [14C]arachidonyl PE and were esti- 
mated to be 0.2 mM and 6600 nmol/mg/30 min, respectively. 
3.3. Characterization of nuclear alkaline PLA2 
The Sephacryl S-300 fraction was used for enzymological 
analyses because the further purified enzyme obtained by im- 
munoaffinity column was very labile and its activity was de- 
creasing day by day. The optimum pH was estimated to be 9-  
10 and the free Ca 2+ concentration for maximal activity was 
1 mM (data not shown). The substrate preference was in the 
order PE, PS, PC, and PI (100:42:23:5). As to the 2-acyl 
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Fig. 1. Distribution of alkaline PLA2 activity in different subnuclear 
fractions. A: Alkaline PLA2 activity was determined under the con- 
ditions as described in Section 2, except hat 5 gl aliquots of each 
10 ml subnuclear fractions derived from 2 ml packed intact nuclei 
were used as an enzyme source. Relative activity was expressed as 
percentage of the total activity of PLA2 in intact nuclei. Nuclei, in- 
tact nuclei; Nuclear Membrane, 1% Triton X-100 soluble fraction 
from intact nuclei; Membrane-depleted Nuclei, 1% Triton X-100 in- 
soluble fraction from intact nuclei; Chromatin, 0.25 M (NH4)2SO4 
soluble fraction from DNase I and RNase digested membrane-de- 
pleted nuclei; Matrix, 0.25 M (NH4)2SO4 insoluble fraction from 
DNase I and RNase digested membrane-depleted nuclei. B: Each 
1 gl from the same nuclear fractions as described in A and rat 
platelet group II PLA2 (5.6 ng) as a positive control were subjected 
to SDS-PAGE/immunoblot analysis using a polyclonal antibody 
against rat group II PLA2 (R377) as described in Section 2. The 
lines show molecular mass standards, from top to bottom: ovalbu- 
min (45 kDa), carbonic anhydrase (31 kDa), soybean trypsin inhib- 
itor (21.5 kDa) and lysozyme (14.4 kDa). The arrow shows the im- 
munostained bands (17 kDa). The result is representative of those 
obtained from three experiments. 
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Fig. 2. Sephacryl S-300 column chromatography. A: 10 ml of 0.25 
M (NH4)2SO4 soluble fraction (56 mg protein) from the digested 
membrane-depleted nuclei was concentrated to 2 ml and applied to 
the Sephacryl S-300 column (1.2×85 cm) equilibrated with a solu- 
tion containing 0.25 M (NH4)2SO4, 20 mM Tris/HCl (pH 7.2) and 
0.1 mM PMSF. The column was eluted with 200 ml of the same so- 
lution as described above and 10 ~tl aliquots of each fraction (2 ml) 
were subjected to the assay of PLA2 activity as described in Section 
2. Solid line without symbols, optical density at 280 nm; solid line 
with symbols, PLA2 activity. The result is representative of those 
obtained from six experiments. B: The pooled active fraction (frac- 
tions 51~70 in Fig. 1A) was concentrated to 2 ml and subjected to 
rechromatography using the same column as in A. 10 ~tl aliquots of 
each fraction (2 ml) were assayed for PLA2 activity at pH 7.0 (©) 
or pH 9.5 (11) as described in Section 2. C: 2 lal aliquots of each 
fraction (2 ml) were subjected to SDS-PAGE/immunoblot analysis 
using a polyclonal antibody against rat group II PLA2 (R337) as 
described in Section 2. The lines show molecular mass standards, 
from top to bottom: carbonic anhydrase (31 kDa), soybean trypsin 
inhibitor (21.5 kDa) and lysozyme (14.4 kDa). The arrow shows the 
immunostained bands (17 kDa). 
moiety of PE, linoleic acid and oleic acid were hydrolyzed 
twice as efficiently as arachidonic acid, indicating that the 
specificity of the 2-acyl moiety is not as strict as that of cyto- 
solic PLA2 [24]. This specificity of the 2-acyl moiety of PE was 
also true in the enzyme purified from immunoaffinity column. 
These characteristics of nuclear alkaline PLAT were quite sim- 
ilar to those of rat group II PLA2 [13,24]. 
3.4. Immunoeytochemical detection of nuclear alkaline PLA2 
AH7974 cells are island-forming type hepatoma cells and 
they grow as aggregates of several cells to form islands (Fig. 
4C). When immunostained with anti-group II PLA2 serum, 
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nuclei were clearly stained, but either plasma membrane or 
cytoplasm was stained only weakly (Fig. 4A). In contrast, 
they were not stained with non-immune serum (Fig. 4B). 
4. Discussion 
We previously described that rat ascites hepatoma AH7974 
cells contain a modest level of PLA2 [9], while normal rat liver 
hepatocytes have been reported to contain very low amounts 
of PLA2 undetectable by immunocytochemical nalysis 
[10,25]. Group II PLA2 was shown to be expressed in human 
hepatoma [26]. It was also revealed that two kinds of PLA2, 
alkaline and neutral PLA2, exist in nuclei of rat ascites hepa- 
toma AH7974 cells [9]. In the present study, it was found that 
the nuclear alkaline PLA2 reacted well with antibody raised 
against rat platelet group II PLA2 [17]. Taking advantage of 
this cross-reactivity, the alkaline PLA2 was purified from nu- 
clear extract using an immunoaffinity column with a mono- 
clonal antibody against rat group II PLA2 [17]. The purified 
enzyme was very similar to rat group II PLA2 with respect o 
substrate specificity, Ca 2+ requirement and apparent molecu- 
lar mass estimated from its mobility on SDS-PAGE [13,24]. 
Although the fatty acid-releasing activity under alkaline con- 
dition was detected in all subcellular fractions of AH7974 
cells, the total activity was highest in nuclei (52%, data not 
shown). Since the alkaline PLA2 activity in the intact nuclei 
top 
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Fig. 3. Immunoaffinity column chromatography. A: The active frac- 
tions obtained from Sephacryl S-300 column chromatography (Fig. 
1A) were pooled and applied to monoclonal antibody against rat 
group II PLA2 (MD 7.1)-coated Sepharose column (1.5×2 cm) 
equilibrated with a solution containing 10 mM Tris/HCl (pH 7.4), 
1 mM EDTA and 1 M KCI. The column was eluted with 20 ml of 20 
mM glycine/HCl (pH 2.5) and 50 ~tl aliquots of each fraction (1 ml) 
were subjected to SDS-PAGE and stained with a silver reagent as 
described in Section 2. The arrow shows the protein band of which 
the intensity parallels PLA2 activity. The lines indicate molecular 
mass standards, from top to bottom: bovine serum albumin (66.2 
kDa), ovalbumin (45 kDa), carbonic anhydrase (31 kDa), soybean 
trypsin inhibitor (21.5 kDa) and lysozyme (14.4 kDa). B: 50 I~1 ali- 
quots of each fraction (1 ml) and rat group II PLA2 purified from 
rat platelets (2 ng, lane C) were subjected to SDS-PAGE/immuno- 
blot analysis using a polyclonal antibody against rat group II PLA2 
(R377) as described in Section 2. The lines indicate molecular mass 
standards, from top to bottom: carbonic anhydrase (31 kDa), soy- 
bean trypsin inhibitor (21.5 kDa) and lysozyme (14.4 kDa). The ar- 
row shows the immunostained band (17 kDa). The result is repre- 
sentative of those obtained from three independent experiments. 
Fig. 4. Immunocytochemical localization of group lI PLA2 in 
AH7974 cells. AH7974 cells were immunostained with anti-group II
PLA2 rabbit serum (A) and a non-immune rabbit serum (B) as de- 
scribed in Section 2. AH7974 cells were also stained with hematoxy- 
lin-eosin (C). 1400×. 
was recovered more than 100% in the denuded nuclei by 1% 
Triton X-100 treatment (Fig. 1A), it was strongly suggested 
that the activity was of nuclear origin. In support of this, 
immunostaining of AH7974 cells with anti-group II PLA2 
antibody preferentially stained nuclei (Fig. 4A). The alkaline 
PLA2 activities in both intact nuclei and partially purified 
preparation were inhibited ose-dependently by an anti-group 
II PLA2 antibody to 20% of the original activity. These results 
indicate that the larger part of alkaline PLA2 activity in 
AH7974 nuclei is closely related with group II PLA2. 
Aarsman et al. [5] reported that PLA2 from rat liver mito- 
chondria has 100% sequence homology to the N-terminal 24 
amino acids of rat group II enzyme. Our results combined 
with previous reports by other groups [24] may be relevant 
to an important question: whether very similar but distinct 
types of group II PLA2 isozyme are expressed in the organ- 
specific manner and localize in different organelles in different 
cells, or a single type of group II PLA2 exists in all tissues but 
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localizes differently in organelles depending on each cell type. 
The fact that the nuclear alkaline PLA2 described here is 
immunochemically indistinguishable from group II PLA2 of 
rat platelets that have no nuclei may support he latter possi- 
bility, but the conclusion must wait for further study. The 
mechanism of transportation of the group II-like PLA2 into 
nuclei from either outside or inside cells also remains un- 
known. 
It should be noted that the nuclear group II-like PLA2 
could be solubilized only from nuclease-digested nuclei with 
0.25 M (NH4)2SO4. The existence of group II PLA2 in nuclei- 
containing fractions has been reported in human placenta [12] 
and rat spleen and liver cells [10,27] and its solubilization was 
reported to be rather difficult. These facts suggest hat nuclear 
group II-like PLA2 transported from either outside or inside 
cells tightly binds to negatively charged nucleic acids, just as 
in the case of the secreted group II PLA,, which binds to 
negatively charged heparan sulfate proteoglycan i the surface 
of the target cells [28]. Recently, Bennett et al. [29] have re- 
ported that phosphorothionate oligonucleotides containing G- 
quartet directly inhibited human group II PLA2 activity in a 
sequence-specific manner. Whether the nuclear group II-like 
PLA2 binds to a specific DNA sequence or not is under in- 
vestigation in our laboratory. 
The exact mechanism how this enzyme protein carrying 
signal peptide distributes in nuclei is yet to be clarified, 
although several mechanisms including post-translational 
modification of enzyme protein have been hypothesized 
[25,30]. 
We have previously reported that the rapid turnover of the 
acyl chain at the 2 position of nuclear phospholipids can be 
induced by proliferating stimuli: the transient increase of oleic 
acid at the expense of arachidonic acid and docosahexaenoic 
acid [16]. Neufeld et al. [31] reported that [3H]arachidonate 
was rapidly incorporated into the nuclear membrane of mur- 
ine fibrosarcoma cells. Capriotti et al. [32] also reported that, 
in mouse fibrosarcoma cells, the most recently incorporated 
pool of arachidonate in the nuclear membrane was preferen- 
tially released upon stimulation by bradykinin. Further, the 
prostaglandin- and leukotriene-synthesizing enzymes have 
been reported to exist in the nuclei [33-39]. Interestingly, cy- 
clooxygenase-2, which is induced by agonist stimulation, has 
been found largely in nuclei, while a constitutive nzyme, 
cyclooxygenase-1, exists only in endoplasmic reticulum and 
not in nuclei [39]. Since phospholipids exist in chromatin 
[40] as well as in the nuclear membrane, it is strongly sug- 
gested that nuclear group II-like PLA2 associated with chro- 
matin may play an important role in the regulation of nuclear 
function through the production of various bioactive sub- 
stances by hydrolyzing the phospholipids of chromatin and/ 
or the nuclear membrane. 
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